BioSpace News Archive

According to Emergen Research, the global AI-based clinical trials solution provider market size was USD 1.24 Billion in 2020 and is expected to reach USD 5.86 Billion in 2028 and register a revenue CAGR of 21.5% during the forecast period, 2021-2028.

IO Biotech today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial in Nature Medicine that can be found HERE.

NEOGEN Corporation (NASDAQ: NEOG) announced today that it has acquired Spokane, Washington -based companion animal genetic testing company Genetic Veterinary Sciences, Inc.

Capsida Biotherapeutics, Inc.,today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in the brain and decreased liver targeting following intravenous (IV) administration in rodents and non-human primates.

Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.

The following is attributed to Frank Yiannas, FDA Deputy Commissioner for Food Policy and Response, and Stic Harris, D.V.M. director of the FDA’s Coordinated Outbreak Response and Evaluation Network.

Seattle Cancer Care Alliance, the only National Comprehensive Cancer Network -designated cancer center in Washington state, announced that more than 20 of the organization’s clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology, taking place December 11-14, 2021, in Atlanta.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021.

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).

iTeos Therapeutics, Inc. (Nasdaq: ITOS), today announced the presentation of new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.